EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real‐World Efficacy of Extending Duration of Letermovir Prophylaxis for Allogeneic Stem Cell Recipients

Yasutaka Masuda, Takashi Toya, Riki Yamakawa, Kairi Kojo, Kana Kato, Yasutaka Sadaga, Kaori Kondo, Chika Kato, Hiroki Hatsusawa, Fumihiko Ouchi, Yukie Terasaki, Masashi Shimabukuro, Atsushi Jinguji, Hiroaki Shimizu, Yuho Najima, Noriko Doki

Transplant Infectious Disease · 2025-11 · 27 (6)

DOI: 10.1111/tid.70116 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Cytomegalovirus (CMV) reactivation following allogeneic hematopoietic stem cell transplantation (HSCT) leads to significant morbidity and mortality. Recently, a pivotal trial demonstrated extended duration of letermovir until post‐HSCT Day 200 reduced clinically significant CMV infection (csCMVi). Here we evaluated the real‐world efficacy of extended letermovir. Methods We retrospectively reviewed consecutive patients who underwent HSCT and received letermovir prophylaxis for CMV seropositivity of the donor and/or the recipient at a transplant center between July 2018 and March 2024. Results A total of 236 HSCTs with letermovir prophylaxis were performed. Letermovir was administered until Days 75–125 in 189 cases, and until Day 150‐ in 37 cases, who were assigned as short and extended letermovir group, respectively. The cumulative incidence of csCMVi at Day 200 was significantly lower in cases with extended letermovir, with no patient developed csCMVi in this group compared to 26.8% in short prophylaxis group ( p < 0.001). However, the incidence was comparable at Day 400, with 19.7% in extended and 28.4% in short prophylaxis group ( p = 0.14). Multivariable analysis for csCMVi showed age ≥ 50 years at HSCT (hazard ratio [HR], 3.24; p < 0.001) and steroid administration at letermovir discontinuation (HR, 2.25; p = 0.003) were identified as significant risk factors, and patients with both factors were associated with higher incidence of csCMVi regardless of letermovir duration. Immunoglobulin G, but not lymphocyte count, was persistently lower in these high‐risk patients until Day 400. Conclusion Despite the efficacy of letermovir in preventing csCMVi during immunosuppression, the occurrence of csCMVi following letermovir cessation was still a clinical concern. image

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →